Recent advance in clinical application of ticagrelor in acute ischemic stroke
10.3760/cma.j.cn115354-20250327-00173
- VernacularTitle:替格瑞洛在急性缺血性脑卒中的应用研究进展
- Author:
Chengyang SU
1
;
Xiaoqing LU
;
Zhipeng AN
;
Caizhen LI
;
Tiaowen LING
;
Jianghua SI
;
Cheng YU
Author Information
1. 兰州市第一人民医院神经内科，兰州 730050
- Publication Type:Journal Article
- Keywords:
Ticagrelor;
Acute ischemic stroke;
Platelet;
Atherosclerosis;
Randomized controlled trial;
Guideline
- From:
Chinese Journal of Neuromedicine
2025;24(10):1058-1063
- CountryChina
- Language:Chinese
-
Abstract:
Atherosclerosis is the most common cause of ischemic stroke. Antiplatelet aggregation is considered as the effective treatment for atherosclerotic ischemic stroke. Ticagrelor is a novel P2Y12 receptor antagonist, which has the advantages as rapid onset, strong effect, no need for liver metabolism activation and reversible platelet inhibition. Studies have confirmed that ticagrelor has a better therapeutic effect on ischemic stroke patients who are resistant to clopidogrel; especially in dual antiplatelet therapy, patients used ticagrelor have lower stroke risk and severe hemorrhage risk does not increase in these patients. This article reviews the recent advances in mechanism of ticagrelor and its application in acute ischemic stroke, with the aim of providing references for clinical application of ticagrelor.
